NEW YORK – The European Commission has approved a high-dose regimen of Biogen's Spinraza (nusinersen), an antisense oligonucleotide for 5q spinal muscular atrophy (SMA).

The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to ...

SOUTH SAN FRANCISCO, Calif., January 12, 2026--insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML™ ...

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we ...

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.

Codexis expands reach of the ECO Synthesis Manufacturing Platform through a signed evaluation agreement with Axolabs for oligonucleotide therapeutics: Redwood City, California Mon ...

Codexis Inc. and Axolabs have entered into an agreement under which Axolabs will evaluate Codexis’ ECO Synthesis ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.